000 03752naa a22006257i 4500
001 UMUN-OA-20261005-MLS-050
003 local
005 20261005174905.0
006 m o d
007 cr||||||||||||
008 261005s2020 xx o u000 0 eng d
024 7 _a10.1007/s00428-020-02928-z
_2doi
035 _a(local)EuropePMC:PMC7550230
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aK Dufraing
_eauthor.
245 1 0 _aBiomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. /
_cK Dufraing; F Fenizia; E Torlakovic [and others].
264 1 _a[Place of publication not identified] :
_b[publisher not identified],
_c2020.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aIn personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA programs for different cancer types, test methods, and sample types. In 2013, a guideline was published on the requirements for organizing high-quality EQA programs in molecular pathology. Now, after six years, steps were taken to further harmonize these EQA programs as an initiative by IQNPath ABSL, an umbrella organization founded by various EQA providers. This revision is based on current knowledge, adds recommendations for programs developed for predictive biomarkers by in situ methodologies (immunohistochemistry and in situ hybridization), and emphasized transparency and an evidence-based approach. In addition, this updated version also has the aim to give an overview of current practices from various EQA providers.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttp://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aImmunohistochemistry
650 4 _aGuideline
650 4 _aOncology
650 4 _ain situ Hybridization
650 4 _aMolecular Pathology
650 4 _aProficiency Testing
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _alaboratory quality
655 4 _aReview articles.
700 0 _aF Fenizia
_eauthor.
700 0 _aE Torlakovic
_eauthor.
700 0 _aN Wolstenholme
_eauthor.
700 0 _aZ C Deans
_eauthor.
700 0 _aE Rouleau
_eauthor.
700 0 _aM Vyberg
_eauthor.
700 0 _aS Parry
_eauthor.
700 0 _aE Schuuring
_eauthor.
700 0 _aElisabeth M C Dequeker
_eauthor.
700 0 _a
_eauthor.
773 0 _tVirchows Archiv : an international journal of pathology
_gVol. 478, no. 3, (2020), pages/article 553-565
_x0945-6317
856 4 0 _uhttps://europepmc.org/articles/PMC7550230
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC7550230
_qlocal
942 _n0
999 _c1192
_d1192